Swiss stocks - Factors to watch on June 1
Swiss stocks - Factors to watch on June 1 ZURICH/GDANSK, June 1 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday:
NOVARTIS NOVN.S
The company said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in patients previously treated with its older drug Pluvicto.
COMPANY STATEMENTS
OCULIS HOLDING CR5.F
The company said on Friday its eye drop for patients with diabetic macular edema failed to meet the main goal of improving vision after 52 weeks in two late-stage trials.
ANALYSTS' VIEWS
OCULIS HOLDING AG : LEERINK PARTNERS CUTS TARGET PRICE TO $40 FROM $50
ECONOMY
*Swiss April retail sales due at 0630 GMT.
*Swiss Q1 GDP due at 0700 GMT.
*Swiss May Manufacturing PMI due at 0730 GMT.
*SNB sight deposits due at 0800 GMT.
(Reporting by Zurich newsroom and Gdansk newsroom)
((+41 58 306 7336; zurich.newsroom@thomsonreuters.com))
For Top News in a multimedia Web format on Eikon visit: https://bit.ly/2NDFd6g
FOR RELATED PRICES, NEWS AND OTHER TOPICS, DOUBLE-CLICK ON:
Daily Swiss stock market report in German .SDE
All SMI constituent stocks 0#.SSMI
DJ STOXX index .STOXX
Top 10 STOXX sectors .PGL.STOXXS
Top 10 EUROSTOXX sectors .PGL.STOXXES
Swiss mid-cap index .SSMI
Swiss all-share index .SSHI
Swiss market digest .AD.S
Sector overview CH/SECTOR1
All Swiss news CH
Swiss research news CH-RCH
All equity news E
SPEED GUIDES: EQUITY, EQUITY/NEWS1, EUR/EQUITY, SWITZERLAND, REUTERS
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'